UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2326-2
Program Prior Authorization/Medical Necessity
Medication Wainua™ (eplontersen)
P&T Approval Date 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Wainua (eplontersen) is a transthyretin-directed antisense oligonucleotide indicated for the
treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in
adults.
2. Coverage Criteria a:
A. Initial Authorization
1. Wainua will be approved based on all of the following criteria:
a. Both of the following:
(1) Diagnosis of hATTR amyloidosis with polyneuropathy
-AND-
(2) Documentation that the patient has a pathogenic TTR mutation (e.g., V30M)
-AND-
b. Prescribed by or in consultation with a neurologist
-AND-
c. Documentation of one of the following:
(1) Patient has a baseline polyneuropathy disability (PND) score ≤ IIIb
-OR-
(2) Patient has a baseline FAP Stage 1 or 2
-OR-
(3) Patient has a baseline neuropathy impairment (NIS) score ≥ 10 and ≤ 130
-AND-
d. Patient has not had a liver transplant
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
e. Presence of clinical signs and symptoms of the disease (e.g., peripheral
sensorimotor polyneuropathy, autonomic neuropathy, motor disability, etc.)
-AND-
f. Patient is not receiving Wainua in combination with either of the following:
(1) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran),
Tegsedi (inotersen)]
-OR-
(2) Transthyretin stabilizer [e.g., Vyndaqel/Vyndamax (tafamadis), Attruby
(acoramidis)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Wainua will be approved based on both of the following criteria:
a. Documentation that the patient has experienced a positive clinical response to
Wainua therapy (e.g., improved neurologic impairment, motor function, quality of
life, slowing of disease progression, etc.)
-AND-
b. Patient is not receiving Wainua in combination with either of the following:
(1) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran),
Tegsedi (inotersen)]
-OR-
(2) Transthyretin stabilizer [e.g., Vyndaqel/Vyndamax (tafamadis), Attruby
(acoramidis)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Wainua [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2024.
Program Prior Authorization/Medical Necessity - Wainua™ (eplontersen)
Change Control
2/2024 New program.
2/2025 Added Attruby to Vyndaqel/Vyndamax and relabeled as transthyretin
stabilizer agents not to be used in combination. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
3